Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Here's a recap of the week’s most important stories.

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Nike is raising prices on a range of merchandise as it braces for tariffs to hit its profits and tries to carry out a ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced promising results from its Phase 3 trial of Acoramidis, showing its ability to ...

BMO Capital Markets reaffirmed its “Market Perform” rating and $64.00 price target for Novo Nordisk A/S (NYSE:NVO) following the announcement of a CEO transition. Analysts view the leadership change ...

Novo Nordisk ( NVO -1.33%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...

That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

Regional equity markets closed in positive territory on Tuesday, building positive momentum after a muted trading session on ...

HONG KONG (AP) — Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the ...